The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A modular, multi-arm, multi-part, first time in patient study to evaluate the safety and tolerability of the dual MET kinase/OCT2 inhibitor, OMO-1, alone and in combination with anti-cancer treatments, in patients with locally advanced, unresectable or metastatic solid malignancies.
 
Elizabeth Ruth Plummer
Honoraria - Bristol-Myers Squibb; Pfizer (I); Roche/Genentech
Consulting or Advisory Role - Astex Pharmaceuticals; Bayer; Clovis Oncology; Modulatex; MSD Oncology; Novartis; Octimet; Pierre Fabre; Roche/Genentech; Vertex
Speakers' Bureau - Novartis
Research Funding - AstraZeneca/MedImmune (Inst)
Patents, Royalties, Other Intellectual Property - Named on patent of use of PARP inhibitor rucaparib (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD Oncology
 
Martijn P. Lolkema
Consulting or Advisory Role - Incyte (Inst); Johnson & Johnson
Research Funding - Astellas Medivation (Inst); Johnson & Johnson (Inst); MSD (Inst); Sanofi (Inst)
 
Joachim G.J.V. Aerts
Stock and Other Ownership Interests - Amphera
Consulting or Advisory Role - Amphera; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD Oncology; Roche/Genentech
Speakers' Bureau - AstraZeneca
Patents, Royalties, Other Intellectual Property - an allogenic lysate for vaccination (Inst)
 
Filip Yves Francine Leon De Vos
Research Funding - Abbvie (Inst); BioClin Therapeutics (Inst); Novartis (Inst)
 
Martin Forster
No Relationships to Disclose
 
ERIC ANGEVIN
No Relationships to Disclose
 
Rebecca Sophie Kristeleit
Honoraria - AstraZeneca; Clovis Oncology; Roche/Genentech; Tesaro
Consulting or Advisory Role - Basilea; Cerulean Pharma; Clovis Oncology; Roche/Genentech; Sotio
Travel, Accommodations, Expenses - Basilea; Clovis Oncology; Valirx
 
Tim Perera
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Johnson & Johnson; Octimet
Research Funding - Octimet
Patents, Royalties, Other Intellectual Property - Johnson & Johnson; Octimet
 
Glen Clack
Employment - Aptus Clinical; Aptus Clinical; AstraZeneca; AstraZeneca; Carrick Therapeutics; Carrick Therapeutics; iOMEDICO; iOMEDICO; MorEx; MorEx; Octimet; Octimet; PCI Biotech; PCI Biotech; Redx Pharma; Redx Pharma
Stock and Other Ownership Interests - Carrick Therapeutics; Octimet
 
Ann Meulemans
Employment - Octimet
Leadership - Octimet
Stock and Other Ownership Interests - Octimet
Consulting or Advisory Role - Octimet
 
Marion Libouban
Stock and Other Ownership Interests - Octimet
 
Prashanth Hari Dass
No Relationships to Disclose
 
Yvette Drew
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Clovis Oncology
Speakers' Bureau - AstraZeneca
Research Funding - Clovis Oncology (Inst); Verastem (Inst)
Travel, Accommodations, Expenses - Clovis Oncology
 
Nadina Tinsley
No Relationships to Disclose
 
Shankar Balaratnam
No Relationships to Disclose
 
Sarah Patricia Blagden
Stock and Other Ownership Interests - RNA Guardian; RNA Guardian (I)
Speakers' Bureau - Clovis Oncology; OCTIMET
Research Funding - Incyte (Inst); Nucana (Inst); octimet (Inst); Piqur (Inst); Redx Pharma (Inst); Sierra Pharma (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - WO 2016075455 A1 circulating LARP1
Travel, Accommodations, Expenses - Nucana; Tesaro
 
Matthew Krebs
Honoraria - Roche
Consulting or Advisory Role - Achilles Therapeutics; Octimet; Roche
Travel, Accommodations, Expenses - AstraZeneca